Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an announcement.
Shanghai Henlius Biotech, Inc. announced that the first patient has been dosed in a phase 2 clinical study of their innovative product HLX22, in combination with trastuzumab deruxtecan, for treating HER2-low, HR-positive locally advanced or metastatic breast cancer in mainland China. This study aims to evaluate the efficacy and safety of this combination therapy, which has shown promising preclinical results, potentially offering a new therapeutic strategy for patients with HER2-expressing tumors.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of innovative monoclonal antibodies for the treatment of various cancers, including gastric and breast cancer. The company is engaged in clinical trials for its products, including HLX22, which has potential indications for multiple solid tumors.
YTD Price Performance: 35.02%
Average Trading Volume: 1,694,735
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.31B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.